The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer
2008
The Role of PPARγ Receptors and Leukotriene B4 Receptors in Pancreatic Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): Adrian Thomas E., Hennig Rene, Friess Helmut, Ding Xianzhong
Hypothesis
The effects of LY293111 may be mediated by both LTB4 receptors and PPARγ.
Conclusion
LY293111 shows potential anticancer effects in pancreatic cancer by acting on multiple targets.
Supporting Evidence
- LY293111 inhibits proliferation and induces apoptosis in pancreatic cancer cells.
- The drug acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.
- LY293111 has shown to enhance the effects of gemcitabine in cancer treatment.
Takeaway
LY293111 is a drug that might help treat pancreatic cancer by blocking certain receptors and causing cancer cells to die.
Methodology
The study involved in vitro and in vivo experiments to assess the effects of LY293111 on pancreatic cancer cells.
Limitations
The evidence regarding the mechanisms of action of LY293111 is not conclusive.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website